A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/42 (2006.01) C07K 16/08 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2079230
A method of treating EBV infections is provided. The method comprises administering an effective amount of an antagonist to the EBV protein, BCRF1. Preferably, the antagonist is a blocking monoclonal antibody specific for BCRF1, or a fragment or binding composition derived therefrom. The invention includes the use of an antagonist to BCRF1, e.g. for the manufacture of a medicament, for the treatment of Epstein-Barr virus disease.
Procédé de traitement d'infections dues au virus d'Epstein-Barr. Le procédé consiste à administrer une dose efficace d'un antagoniste contre la protéine BCRF1 du virus d'Epstein-Barr. L'antagoniste est de préférence un anticorps monoclonal de blocage spécifique de la BCRF1, ou un fragment ou une composition de liaison dérivée dudit anticorps. L'invention concerne également l'emploi d'un antagoniste contre la BCRF1, par exemple pour la fabrication d'un médicament, destiné au traitement de la maladie provoquée par le virus d'Epstein-Barr.
Schering Corporation
Swabey Ogilvy Renault
LandOfFree
Bcrf1 antagonists for treating epstein-barr virus infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bcrf1 antagonists for treating epstein-barr virus infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bcrf1 antagonists for treating epstein-barr virus infections will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1942455